FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)

Katoh,Masaru

doi:10.3892/ijmm.2016.2620

FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)

Authors:
- Masaru Katoh
View Affiliations

Affiliations: Department of Omics Network, National Cancer Center, Tokyo 104-0045, Japan
Published online on: May 31, 2016 https://doi.org/10.3892/ijmm.2016.2620
Pages: 3-15
Copyright: © Katoh . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fibroblast growth factor (FGF)2, FGF4, FGF7 and FGF20 are representative paracrine FGFs binding to heparan-sulfate proteoglycan and fibroblast growth factor receptors (FGFRs), whereas FGF19, FGF21 and FGF23 are endocrine FGFs binding to Klotho and FGFRs. FGFR1 is relatively frequently amplified and overexpressed in breast and lung cancer, and FGFR2 in gastric cancer. BCR-FGFR1, CNTRL-FGFR1, CUX1-FGFR1, FGFR1OP-FGFR1, MYO18A-FGFR1 and ZMYM2-FGFR1 fusions in myeloproliferative neoplasms are non-receptor-type FGFR kinases, whereas FGFR1-TACC1, FGFR2-AFF3, FGFR2-BICC1, FGFR2-PPHLN1, FGFR3-BAIAP2L1 and FGFR3-TACC3 fusions in solid tumors are transmembrane-type FGFRs with C-terminal alterations. AZD4547, BGJ398 (infigratinib), Debio-1347 and dovitinib are FGFR1/2/3 inhibitors; BLU9931 is a selective FGFR4 inhibitor; FIIN-2, JNJ-42756493, LY2874455 and ponatinib are pan-FGFR inhibitors. AZD4547, dovitinib and ponatinib are multi-kinase inhibitors targeting FGFRs, colony stimulating factor 1 receptor (CSF1R), vascular endothelial growth factor (VEGF)R2, and others. The tumor microenvironment consists of cancer cells and stromal/immune cells, such as cancer-associated fibroblasts (CAFs), endothelial cells, M2-type tumor-associating macrophages (M2-TAMs), myeloid-derived suppressor cells (MDSCs) and regulatory T cells. FGFR inhibitors elicit antitumor effects directly on cancer cells, as well as indirectly through the blockade of paracrine signaling. The dual inhibition of FGF and CSF1 or VEGF signaling is expected to enhance the antitumor effects through the targeting of immune evasion and angiogenesis in the tumor microenvironment. Combination therapy using tyrosine kinase inhibitors (FGFR or CSF1R inhibitors) and immune checkpoint blockers (anti-PD-1 or anti-CTLA-4 monoclonal antibodies) may be a promising choice for cancer patients. The inhibition of FGF19-FGFR4 signaling is associated with a risk of liver toxicity, whereas the activation of FGF23-FGFR4 signaling is associated with a risk of heart toxicity. Endocrine FGF signaling affects the pathophysiology of cancer patients who are prescribed FGFR inhibitors. Whole-genome sequencing is necessary for the detection of promoter/enhancer alterations of FGFR genes and rare alterations of other genes causing FGFR overexpression. To sustain the health care system in an aging society, a benefit-cost analysis should be performed with a focus on disease-free survival and the total medical cost before implementing genome-based precision medicine for cancer patients.

View Figures

View References

1	Lemmon MA and Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010. View Article : Google Scholar : PubMed/NCBI
2	Manning G, Whyte DB, Martinez R, Hunter T and Sudarsanam S: The protein kinase complement of the human genome. Science. 298:1912–1934. 2002. View Article : Google Scholar : PubMed/NCBI
3	Roskoski R Jr: The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014. View Article : Google Scholar
4	Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL and Wilding G: Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol. 23:5474–5483. 2005. View Article : Google Scholar : PubMed/NCBI
5	Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, et al: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 10:2298–2308. 2011. View Article : Google Scholar : PubMed/NCBI
6	Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, et al: Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 56:5675–5690. 2013. View Article : Google Scholar : PubMed/NCBI
7	Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, Botrous I, et al: Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 54:6342–6363. 2011. View Article : Google Scholar : PubMed/NCBI
8	Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M and Funahashi Y: Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014:6387472014. View Article : Google Scholar : PubMed/NCBI
9	O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, et al: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 16:401–412. 2009. View Article : Google Scholar : PubMed/NCBI
10	Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH and Zopf D: Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 129:245–255. 2011. View Article : Google Scholar
11	Chow LQ and Eckhardt SG: Sunitinib: From rational design to clinical efficacy. J Clin Oncol. 25:884–896. 2007. View Article : Google Scholar : PubMed/NCBI
12	Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J and Schlumberger M: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 28:767–772. 2010. View Article : Google Scholar : PubMed/NCBI
13	Eswarakumar VP, Lax I and Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16:139–149. 2005. View Article : Google Scholar : PubMed/NCBI
14	Katoh M and Nakagama H: FGF receptors: Cancer biology and therapeutics. Med Res Rev. 34:280–300. 2014. View Article : Google Scholar
15	Coleman SJ, Bruce C, Chioni AM, Kocher HM and Grose RP: The ins and outs of fibroblast growth factor receptor signalling. Clin Sci (Lond). 127:217–231. 2014. View Article : Google Scholar
16	Ornitz DM and Itoh N: The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 4:215–266. 2015. View Article : Google Scholar : PubMed/NCBI
17	Katoh M: FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies. J Invest Dermatol. 129:1861–1867. 2009. View Article : Google Scholar : PubMed/NCBI
18	Turner N and Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer. 10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI
19	Kelleher FC, O'Sullivan H, Smyth E, McDermott R and Viterbo A: Fibroblast growth factor receptors, developmental corruption and malignant disease. Carcinogenesis. 34:2198–2205. 2013. View Article : Google Scholar : PubMed/NCBI
20	Helsten T, Schwaederle M and Kurzrock R: Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: Biologic and clinical implications. Cancer Metastasis Rev. 34:479–496. 2015. View Article : Google Scholar : PubMed/NCBI
21	Brooks AN, Kilgour E and Smith PD: Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 18:1855–1862. 2012. View Article : Google Scholar : PubMed/NCBI
22	Chang J, Liu X, Wang S, Zhang Z, Wu Z, Zhang X and Li J: Prognostic value of FGFR gene amplification in patients with different types of cancer: A systematic review and meta-analysis. PLoS One. 9:e1055242014. View Article : Google Scholar : PubMed/NCBI
23	Parker BC and Zhang W: Fusion genes in solid tumors: An emerging target for cancer diagnosis and treatment. Chin J Cancer. 32:594–603. 2013. View Article : Google Scholar : PubMed/NCBI
24	Feng S, Zhou L, Nice EC and Huang C: Fibroblast growth factor receptors: Multifactorial-contributors to tumor initiation and progression. Histol Histopathol. 30:13–31. 2015.
25	Liang G, Chen G, Wei X, Zhao Y and Li X: Small molecule inhibition of fibroblast growth factor receptors in cancer. Cytokine Growth Factor Rev. 24:467–475. 2013. View Article : Google Scholar : PubMed/NCBI
26	André F and Cortés J: Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat. 150:1–8. 2015. View Article : Google Scholar : PubMed/NCBI
27	Porta C, Giglione P, Liguigli W and Paglino C: Dovitinib (CHIR258, TKI258): Structure, development and preclinical and clinical activity. Future Oncol. 11:39–50. 2015. View Article : Google Scholar : PubMed/NCBI
28	Carter EP, Fearon AE and Grose RP: Careless talk costs lives: Fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Trends Cell Biol. 25:221–233. 2015. View Article : Google Scholar
29	Chang J, Wang S, Zhang Z, Liu X, Wu Z, Geng R, Ge X, Dai C, Liu R, Zhang Q, et al: Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. Oncotarget. 6:2009–2022. 2015. View Article : Google Scholar : PubMed/NCBI
30	Wang J, Mikse O, Liao RG, Li Y, Tan L, Janne PA, Gray NS, Wong KK and Hammerman PS: Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 34:2167–2177. 2015. View Article : Google Scholar
31	Ronca R, Giacomini A, Rusnati M and Presta M: The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert. Opin Ther Targets. 19:1361–1377. 2015. View Article : Google Scholar
32	Salazar L, Kashiwada T, Krejci P, Meyer AN, Casale M, Hallowell M, Wilcox WR, Donoghue DJ and Thompson LM: Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer. PLoS One. 9:e864702014. View Article : Google Scholar
33	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
34	Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2:62ra932010. View Article : Google Scholar : PubMed/NCBI
35	Cihoric N, Savic S, Schneider S, Ackermann I, Bichsel-Naef M, Schmid RA, Lardinois D, Gugger M, Bubendorf L, Zlobec I, et al: Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. Br J Cancer. 110:2914–2922. 2014. View Article : Google Scholar : PubMed/NCBI
36	Preusser M, Berghoff AS, Berger W, Ilhan-Mutlu A, Dinhof C, Widhalm G, Dieckmann K, Wöhrer A, Hackl M, von Deimling A, et al: High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer. 83:83–89. 2014. View Article : Google Scholar
37	Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, Lee J, Jung YJ, Kim JO, Shin JY, et al: The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 22:2109–2119. 2012. View Article : Google Scholar : PubMed/NCBI
38	Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, et al: Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3:636–647. 2013. View Article : Google Scholar : PubMed/NCBI
39	Tanizaki J, Ercan D, Capelletti M, Dodge M, Xu C, Bahcall M, Tricker EM, Butaney M, Calles A, Sholl LM, et al: Identification of oncogenic and drug-sensitizing mutations in the extracellular domain of FGFR2. Cancer Res. 75:3139–3146. 2015. View Article : Google Scholar : PubMed/NCBI
40	Maxmen A: The hard facts. Nature. 485:S50–S51. 2012. View Article : Google Scholar : PubMed/NCBI
41	Ellis MJ and Perou CM: The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov. 3:27–34. 2013. View Article : Google Scholar : PubMed/NCBI
42	Khoo BL, Lee SC, Kumar P, Tan TZ, Warkiani ME, Ow SG, Nandi S, Lim CT and Thiery JP: Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. Oncotarget. 6:15578–15593. 2015. View Article : Google Scholar : PubMed/NCBI
43	Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, et al: Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 345:216–220. 2014. View Article : Google Scholar : PubMed/NCBI
44	André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-Triki M, Lacroix L, Cohen P, Gentien D, et al: Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: A multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 15:267–274. 2014. View Article : Google Scholar : PubMed/NCBI
45	Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, et al: FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70:2085–2094. 2010. View Article : Google Scholar : PubMed/NCBI
46	Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C and Lunet N: Worldwide trends in gastric cancer mortality 1980–2011 with predictions to 2015, and incidence by subtype. Eur J Cancer. 50:1330–1344. 2014. View Article : Google Scholar : PubMed/NCBI
47	Holbrook JD, Parker JS, Gallagher KT, Halsey WS, Hughes AM, Weigman VJ, Lebowitz PF and Kumar R: Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine. J Transl Med. 9:1192011. View Article : Google Scholar : PubMed/NCBI
48	Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, et al: A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 61:673–684. 2012. View Article : Google Scholar : PubMed/NCBI
49	Jung EJ, Jung EJ, Min SY, Kim MA and Kim WH: Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol. 43:1559–1566. 2012. View Article : Google Scholar : PubMed/NCBI
50	Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X, Shen D, Bang YJ, Im SA, Ho Kim W, et al: FGFR2 amplification has prognostic significance in gastric cancer: Results from a large international multicentre study. Br J Cancer. 110:967–975. 2014. View Article : Google Scholar : PubMed/NCBI
51	Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, et al: FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res. 19:2572–2583. 2013. View Article : Google Scholar : PubMed/NCBI
52	Zhang T, Zhang L, Fan S, Zhang M, Fu H, Liu Y, Yin X, Chen H, Xie L, Zhang J, et al: Patient-derived gastric carcinoma xenograft mouse models faithfully represent human tumor molecular diversity. PLoS One. 10:e01344932015. View Article : Google Scholar : PubMed/NCBI
53	Agelopoulos K, Richter GH, Schmidt E, Dirksen U, von Heyking K, Moser B, Klein HU, Kontny U, Dugas M, Poos K, et al: Deep sequencing in conjunction with expression and functional analyses reveals activation of FGFR1 in Ewing sarcoma. Clin Cancer Res. 21:4935–4946. 2015. View Article : Google Scholar : PubMed/NCBI
54	Reintjes N, Li Y, Becker A, Rohmann E, Schmutzler R and Wollnik B: Activating somatic FGFR2 mutations in breast cancer. PLoS One. 8:e602642013. View Article : Google Scholar : PubMed/NCBI
55	Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, Goodfellow PJ and Pollock PM: FGFR2 point mutations in 466 endometrioid endometrial tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One. 7:e308012012. View Article : Google Scholar : PubMed/NCBI
56	Ross JS, Wang K, Al-Rohil RN, Nazeer T, Sheehan CE, Otto GA, He J, Palmer G, Yelensky R, Lipson D, et al: Advanced urothelial carcinoma: Next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol. 27:271–280. 2014. View Article : Google Scholar
57	Gartside MG, Chen H, Ibrahimi OA, Byron SA, Curtis AV, Wellens CL, Bengston A, Yudt LM, Eliseenkova AV, Ma J, et al: Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res. 7:41–54. 2009. View Article : Google Scholar : PubMed/NCBI
58	Koika V, Varnavas P, Valavani H, Sidis Y, Plummer L, Dwyer A, Quinton R, Kanaka-Gantenbein C, Pitteloud N, Sertedaki A, et al: Comparative functional analysis of two fibroblast growth factor receptor 1 (FGFR1) mutations affecting the same residue (R254W and R254Q) in isolated hypogonadotropic hypogonadism (IHH). Gene. 516:146–151. 2013. View Article : Google Scholar : PubMed/NCBI
59	Villanueva C, Jacobson-Dickman E, Xu C, Manouvrier S, Dwyer AA, Sykiotis GP, Beenken A, Liu Y, Tommiska J, Hu Y, et al: Congenital hypogonadotropic hypogonadism with split hand/foot malformation: A clinical entity with a high frequency of FGFR1 mutations. Genet Med. 17:651–659. 2015. View Article : Google Scholar :
60	Jackson CC, Medeiros LJ and Miranda RN: 8p11 myeloproliferative syndrome: A review. Hum Pathol. 41:461–476. 2010. View Article : Google Scholar : PubMed/NCBI
61	Kumar KR, Chen W, Koduru PR and Luu HS: Myeloid and lymphoid neoplasm with abnormalities of FGFR1 presenting with trilineage blasts and RUNX1 rearrangement: A case report and review of literature. Am J Clin Pathol. 143:738–748. 2015. View Article : Google Scholar : PubMed/NCBI
62	Yagasaki F, Wakao D, Yokoyama Y, Uchida Y, Murohashi I, Kayano H, Taniwaki M, Matsuda A and Bessho M: Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Res. 61:8371–8374. 2001.PubMed/NCBI
63	Ren M, Qin H, Kitamura E and Cowell JK: Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models. Blood. 122:1007–1016. 2013. View Article : Google Scholar : PubMed/NCBI
64	Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, et al: St Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project: Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 45:602–612. 2013. View Article : Google Scholar : PubMed/NCBI
65	Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, Bonal D, Miltiadous O, Zhang Z, Hoshida Y, et al: Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 6:60872015. View Article : Google Scholar : PubMed/NCBI
66	Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, et al: AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72:2045–2056. 2012. View Article : Google Scholar : PubMed/NCBI
67	Kwak Y, Cho H, Hur W and Sim T: Antitumor effects and mechanisms of AZD4547 on FGFR2-deregulated endometrial cancer cells. Mol Cancer Ther. 14:2292–2302. 2015. View Article : Google Scholar : PubMed/NCBI
68	Guagnano V, Kauffmann A, Wöhrle S, Stamm C, Ito M, Barys L, Pornon A, Yao Y, Li F, Zhang Y, et al: FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2:1118–1133. 2012. View Article : Google Scholar : PubMed/NCBI
69	Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N, et al: First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov. 5:424–437. 2015. View Article : Google Scholar : PubMed/NCBI
70	Nakanishi Y, Akiyama N, Tsukaguchi T, Fujii T, Sakata K, Sase H, Isobe T, Morikami K, Shindoh H, Mio T, et al: The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 13:2547–2558. 2014. View Article : Google Scholar : PubMed/NCBI
71	Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, Garrett E, Samara E, Aukerman SL, Gelb AB, et al: In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res. 11:3633–3641. 2005. View Article : Google Scholar : PubMed/NCBI
72	Tan L, Wang J, Tanizaki J, Huang Z, Aref AR, Rusan M, Zhu SJ, Zhang Y, Ercan D, Liao RG, et al: Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci USA. 111:E4869–E4877. 2014. View Article : Google Scholar : PubMed/NCBI
73	Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, et al: Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 33:3401–3408. 2015. View Article : Google Scholar : PubMed/NCBI
74	Zhao G, Li WY, Chen D, Henry JR, Li HY, Chen Z, Zia-Ebrahimi M, Bloem L, Zhai Y, Huss K, et al: A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther. 10:2200–2210. 2011. View Article : Google Scholar : PubMed/NCBI
75	Shah RR and Morganroth J: Update on cardiovascular safety of tyrosine kinase inhibitors: With a special focus on QT interval, left ventricular dysfunction and overall risk/benefit. Drug Saf. 38:693–710. 2015. View Article : Google Scholar : PubMed/NCBI
76	Gacche RN and Meshram RJ: Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy. Biochim Biophys Acta. 1846:161–179. 2014.PubMed/NCBI
77	Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C and Dogné JM: Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: A systematic review and meta-analysis. JAMA Oncol. Feb 4–2016.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
78	Jain RK: Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. J Clin Oncol. 31:2205–2218. 2013. View Article : Google Scholar : PubMed/NCBI
79	Quail DF and Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med. 19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
80	Junttila MR and de Sauvage FJ: Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 501:346–354. 2013. View Article : Google Scholar : PubMed/NCBI
81	Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo SH, Goruppi S, Menietti E, Ostano P, Ala U, et al: Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat Cell Biol. 17:1193–1204. 2015. View Article : Google Scholar : PubMed/NCBI
82	Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, et al: A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2:e392013. View Article : Google Scholar : PubMed/NCBI
83	Suvannasankha A, Tompkins DR, Edwards DF, Petyaykina KV, Crean CD, Fournier PG, Parker JM, Sandusky GE, Ichikawa S, Imel EA, et al: FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget. 6:19647–19660. 2015. View Article : Google Scholar : PubMed/NCBI
84	Weis SM and Cheresh DA: Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med. 17:1359–1370. 2011. View Article : Google Scholar : PubMed/NCBI
85	Bridges E, Oon CE and Harris A: Notch regulation of tumor angiogenesis. Future Oncol. 7:569–588. 2011. View Article : Google Scholar : PubMed/NCBI
86	Katoh M: Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int J Mol Med. 32:763–767. 2013.PubMed/NCBI
87	Schmitt J and Matei D: Targeting angiogenesis in ovarian cancer. Cancer Treat Rev. 38:272–283. 2012. View Article : Google Scholar
88	Goel HL and Mercurio AM: VEGF targets the tumour cell. Nat Rev Cancer. 13:871–882. 2013. View Article : Google Scholar : PubMed/NCBI
89	Oladipupo SS, Smith C, Santeford A, Park C, Sene A, Wiley LA, Osei-Owusu P, Hsu J, Zapata N, Liu F, et al: Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc Natl Acad Sci USA. 111:13379–13384. 2014. View Article : Google Scholar : PubMed/NCBI
90	Xiao L, Yang S, Hao J, Yuan X, Luo W, Jiang L, Hu Y, Fu Z, Zhang Y and Zou C: Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis. Cancer Lett. 359:148–154. 2015. View Article : Google Scholar : PubMed/NCBI
91	Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL and Sood AK: Anti-vascular therapies in ovarian cancer: Moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 34:19–40. 2015. View Article : Google Scholar :
92	Hilbert T and Klaschik S: The angiopoietin/TIE receptor system: Focusing its role for ischemia-reperfusion injury. Cytokine Growth Factor Rev. 26:281–291. 2015. View Article : Google Scholar
93	Fagiani E and Christofori G: Angiopoietins in angiogenesis. Cancer Lett. 328:18–26. 2013. View Article : Google Scholar
94	Zhou W, Wang G and Guo S: Regulation of angiogenesis via Notch signaling in breast cancer and cancer stem cells. Biochim Biophys Acta. 1836:304–320. 2013.PubMed/NCBI
95	Rostama B, Peterson SM, Vary CP and Liaw L: Notch signal integration in the vasculature during remodeling. Vascul Pharmacol. 63:97–104. 2014. View Article : Google Scholar : PubMed/NCBI
96	Zhang P, Yan X, Chen Y, Yang Z and Han H: Notch signaling in blood vessels: From morphogenesis to homeostasis. Sci China Life Sci. 57:774–780. 2014. View Article : Google Scholar : PubMed/NCBI
97	Bertolini F, Marighetti P, Martin-Padura I, Mancuso P, Hu-Lowe DD, Shaked Y and D'Onofrio A: Anti-VEGF and beyond: Shaping a new generation of anti-angiogenic therapies for cancer. Drug Discov Today. 16:1052–1060. 2011. View Article : Google Scholar : PubMed/NCBI
98	Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar : PubMed/NCBI
99	Talmadge JE and Gabrilovich DI: History of myeloid-derived suppressor cells. Nat Rev Cancer. 13:739–752. 2013. View Article : Google Scholar : PubMed/NCBI
100	Mantovani A and Sica A: Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr Opin Immunol. 22:231–237. 2010. View Article : Google Scholar : PubMed/NCBI
101	Sakaguchi S, Miyara M, Costantino CM and Hafler DA: FOXP3⁺ regulatory T cells in the human immune system. Nat Rev Immunol. 10:490–500. 2010. View Article : Google Scholar : PubMed/NCBI
102	Balkwill FR: The chemokine system and cancer. J Pathol. 226:148–157. 2012. View Article : Google Scholar
103	Lippitz BE: Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol. e218–e228. 2013. View Article : Google Scholar : PubMed/NCBI
104	Condamine T, Ramachandran I, Youn JI and Gabrilovich DI: Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med. 66:97–110. 2015. View Article : Google Scholar :
105	Rivera LB and Bergers G: Intertwined regulation of angiogenesis and immunity by myeloid cells. Trends Immunol. 36:240–249. 2015. View Article : Google Scholar : PubMed/NCBI
106	Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, et al: CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology. 61:1591–1602. 2015. View Article : Google Scholar :
107	Holdman XB, Welte T, Rajapakshe K, Pond A, Coarfa C, Mo Q, Huang S, Hilsenbeck SG, Edwards DP, Zhang X, et al: Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer. Breast Cancer Res. 17:1412015. View Article : Google Scholar : PubMed/NCBI
108	Liu L, Ye TH, Han YP, Song H, Zhang YK, Xia Y, Wang NY, Xiong Y, Song XJ, Zhu YX, et al: Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model. Cell Physiol Biochem. 33:633–645. 2014. View Article : Google Scholar : PubMed/NCBI
109	Hume DA and MacDonald KP: Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 119:1810–1820. 2012. View Article : Google Scholar
110	Sieweke MH and Allen JE: Beyond stem cells: Self-renewal of differentiated macrophages. Science. 342:12429742013. View Article : Google Scholar : PubMed/NCBI
111	Hamilton JA and Achuthan A: Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol. 34:81–89. 2013. View Article : Google Scholar
112	Moughon DL, He H, Schokrpur S, Jiang ZK, Yaqoob M, David J, Lin C, Iruela-Arispe ML, Dorigo O and Wu L: Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer. Cancer Res. 75:4742–4752. 2015. View Article : Google Scholar : PubMed/NCBI
113	DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al: Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1:54–67. 2011. View Article : Google Scholar : PubMed/NCBI
114	Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W and Wu L: CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 73:2782–2794. 2013. View Article : Google Scholar : PubMed/NCBI
115	Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, et al: Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 25:846–859. 2014. View Article : Google Scholar : PubMed/NCBI
116	Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E and Bergers G: Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep. 11:577–591. 2015. View Article : Google Scholar : PubMed/NCBI
117	Beenken A and Mohammadi M: The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov. 8:235–253. 2009. View Article : Google Scholar : PubMed/NCBI
118	Degirolamo C, Sabbà C and Moschetta A: Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov. 15:51–69. 2016. View Article : Google Scholar
119	Liu WY, Xie DM, Zhu GQ, Huang GQ, Lin YQ, Wang LR, Shi KQ, Hu B, Braddock M, Chen YP, et al: Targeting fibroblast growth factor 19 in liver disease: A potential biomarker and therapeutic target. Expert. Opin Ther Targets. 19:675–685. 2015. View Article : Google Scholar
120	Pai R, French D, Ma N, Hotzel K, Plise E, Salphati L, Setchell KD, Ware J, Lauriault V, Schutt L, et al: Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. Toxicol Sci. 126:446–456. 2012. View Article : Google Scholar : PubMed/NCBI
121	Ge H, Zhang J, Gong Y, Gupte J, Ye J, Weiszmann J, Samayoa K, Coberly S, Gardner J, Wang H, et al: Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions. J Biol Chem. 289:30470–30480. 2014. View Article : Google Scholar : PubMed/NCBI
122	Silswal N, Touchberry CD, Daniel DR, McCarthy DL, Zhang S, Andresen J, Stubbs JR and Wacker MJ: FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab. 307:E426–E436. 2014. View Article : Google Scholar : PubMed/NCBI
123	Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, et al: Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 22:1020–1032. 2015. View Article : Google Scholar : PubMed/NCBI
124	Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes. Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
125	Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, et al: FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 20:3299–3309. 2014. View Article : Google Scholar : PubMed/NCBI
126	Wöhrle S, Weiss A, Ito M, Kauffmann A, Murakami M, Jagani Z, Thuery A, Bauer-Probst B, Reimann F, Stamm C, et al: Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. PLoS One. 8:e776522013. View Article : Google Scholar : PubMed/NCBI
127	Künstlinger H, Fassunke J, Schildhaus HU, Brors B, Heydt C, Ihle MA, Mechtersheimer G, Wardelmann E, Büttner R and Merkelbach-Bruse S: FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro. Oncotarget. 6:20215–20230. 2015. View Article : Google Scholar : PubMed/NCBI
128	Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, et al: Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 346:256–259. 2014. View Article : Google Scholar : PubMed/NCBI
129	Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, et al: The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 526:263–267. 2015. View Article : Google Scholar : PubMed/NCBI
130	Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, et al: Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 346:1480–1486. 2014. View Article : Google Scholar : PubMed/NCBI
131	Chell V, Balmanno K, Little AS, Wilson M, Andrews S, Blockley L, Hampson M, Gavine PR and Cook SJ: Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene. 32:3059–3070. 2013. View Article : Google Scholar
132	Ang D, Ballard M, Beadling C, Warrick A, Schilling A, O'Gara R, Pukay M, Neff TL, West RB, Corless CL, et al: Novel mutations in neuroendocrine carcinoma of the breast: Possible therapeutic targets. Appl Immunohistochem Mol Morphol. 23:97–103. 2015. View Article : Google Scholar : PubMed/NCBI
133	Okazaki T and Honjo T: PD-1 and PD-1 ligands: From discovery to clinical application. Int Immunol. 19:813–824. 2007. View Article : Google Scholar : PubMed/NCBI
134	Sharma P and Allison JP: The future of immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
135	Topalian SL, Drake CG and Pardoll DM: Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI
136	Mahoney KM, Rennert PD and Freeman GJ: Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 14:561–584. 2015. View Article : Google Scholar : PubMed/NCBI
137	Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, Bandla S, Bien G, Choppa P, Hyland F, et al: Development and validation of a scalable next-generation sequencing.